Mutations of the BRAF Gene in Benign and Malignant Melanocytic Lesions

Journal of Investigative Dermatology

Volumn 121, Issue 5, 2003, Pages 1160-1162

  Yazdi, Amir S ^a   Palmedo, Gabriele ^b   Flaig, Michael J ^a   Puchta, Ursula ^a   Reckwerth, Andrea ^b   Rütten, Arno ^b   Mentzel, Thomas ^b   Hügel, Heino ^b   Hantschke, Markus ^b   Schmid Wendtner, Monika Hildegard ^a   Kutzner, Heinz ^b   Sander, Christian A ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b Dermatopathologische Gemeinschaftspraxis   (Germany)

^c NONE   (Germany)

Author keywords

b raf; Nevus; Point mutation

Indexed keywords

ARTICLE; BLUE NEVUS; BRAF GENE; CARCINOMA IN SITU; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSPLASTIC NEVUS; EVALUATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; JUVENILE MELANOMA; MELANOCYTIC NEVUS; MELANOMA; MELANOMA CELL; MUTATOR GENE; NEVUS; POINT MUTATION; PRIORITY JOURNAL;

EID: 10744222648     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2003.12559.x     Document Type: Article

References (15)

1. Bastian BC, LeBoit PE, Pinkel D: Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 157:967-972, 2000
2. Campisi J: Cancer, aging and cellular senescence. In Vivo 14:183-188, 2000
3. Cohen C, Zavala-Pompa A, Sequeira JH, et al: Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8:3728-3733, 2002
4. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
5. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
6. Favata MF, Horiuchi KY, Manos EJ, et al: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273:18623-18632, 1998
7. Govindarajan B, Bai X, Cohen C, et al: Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 278:9790-9795, 2003
8. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
9. Hashemi J, Lindstrom M, Asker C, Platz A, Hansson J, Wiman K: A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF. Cancer Lett 180:211, 2002
10. Lang J, Boxer M, MacKie R: Absence of exon 15 BRAF germline mutations in familial melanoma. Hum Mutat 21:327-330, 2003
11. Pollock PM, Harper UL, Hansen KS, et al: High frequency of BRAF mutations in nevi. Nat Genet 33:19-20, 2003
12. Pollock PM, Meltzer PS: Lucky draw in the gene raffle. Nature 417:906-907, 2002
13. Shibata DK, Arnheim N, Martin WJ: Detection of human papilloma virus in paraffin-embedded tissue using the polymerase chain reaction. J Exp Med 167: 225-230, 1988
14. Stolz W, Schmoeckel C, Landthaler M, Braun-Falco O: Association of early malignant melanoma with nevocytic nevi. Cancer 63:550-555, 1989
15. Urso C, Giannotti V, Reali UM, Giannotti B, Bondi R: Spatial association of melanocytic naevus and melanoma. Melanoma Res 1:245-249, 1991